Page last updated: 2024-08-23

staurosporine and su 11248

staurosporine has been researched along with su 11248 in 28 studies

Research

Studies (28)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's10 (35.71)29.6817
2010's17 (60.71)24.3611
2020's1 (3.57)2.80

Authors

AuthorsStudies
Atteridge, CE; Azimioara, MD; Benedetti, MG; Biggs, WH; Carter, TA; Ciceri, P; Edeen, PT; Fabian, MA; Floyd, M; Ford, JM; Galvin, M; Gerlach, JL; Grotzfeld, RM; Herrgard, S; Insko, DE; Insko, MA; Lai, AG; Lélias, JM; Lockhart, DJ; Mehta, SA; Milanov, ZV; Patel, HK; Treiber, DK; Velasco, AM; Wodicka, LM; Zarrinkar, PP1
Giranda, VL; Johnson, EF; Luo, Y; Stewart, KD; Woods, KW1
Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M1
Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Fales, HM; Gottesman, MM; Hall, MD; Hellawell, JL; Hibbs, DE; Kensler, CB; Ludwig, JA; Salam, NK; Szakács, G1
Russu, WA; Shallal, HM1
Andreani, A; Granaiola, M; Kondapaka, S; Lannigan, D; Leoni, A; Locatelli, A; Morigi, R; Rambaldi, M; Scudiero, D; Shoemaker, RH; Smith, J; Varoli, L1
Hixon, MS; Hori, A; Imamura, S; Iwata, H; Kimura, H; Miki, H1
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Al-Mazaideh, GM; Erdmann, F; Göllner, C; Rohe, A; Schmidt, M; Sippl, W; Wichapong, K1
Amombo, GM; Baumann, K; Fach, M; Göring, S; Kolb, S; Kramer, T; Lo Monte, F; Schmidt, B; Schubenel, R; Smith, S1
Doddareddy, MR; Kassiou, M; Kavanagh, ME1
Chang, PT; Chen, GS; Chern, JW; Jagtap, AD; Kondekar, NB; Liu, JR; Shen, LJ; Tseng, HW; Wang, HC1
Chen, Y; Jiao, Y; Lu, T; Wang, L; Zhang, D; Zhang, Y1
Chen, Y; Gao, L; Li, J; Lu, W; Shen, Q; Tong, L; Zhang, Q1
Abdel-Aziz, AK; Abouzid, KAM; Dokla, EME; McPhillie, MJ; Milik, SN; Minucci, S1
Kiyoi, H1
von Mehren, M1
Duyster, J; Grundler, R; Kancha, RK; Peschel, C1
Bui, B; Italiano, A1
Ehninger, G; Illmer, T1
Levis, M; Murphy, KM; Pratz, KW; Rajkhowa, T; Sato, T; Stine, A1
Ashman, LK; Griffith, R; Mashkani, B1
Chabner, BA; Fathi, AT1
Akita, K; Fujii, I; Gouda, M; Ishihama, Y; Kirii, Y; Kitagawa, D; Narumi, Y; Sugiyama, N; Yokota, K1
Fiedler, W; Wellbrock, J1
Albers, C; Duyster, J; Illert, AL; Leischner, H; Peschel, C; Verbeek, M; von Bubnoff, N; Yu, C1
Bennett, KL; Borgdorff, V; Breitwieser, FP; Colinge, J; Gridling, M; Müller, AC; Rix, U; Superti-Furga, G; Wagner, C; Wagner, SN; Winter, GE1

Reviews

5 review(s) available for staurosporine and su 11248

ArticleYear
[Possibility of targeting FLT3 kinase for the treatment of leukemia].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2005, Volume: 46, Issue:3

    Topics: Animals; Antibodies, Monoclonal; Benzoquinones; Carbazoles; Drug Design; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Lactams, Macrocyclic; Leukemia; Mutation; Piperazines; Pyrroles; Quinazolines; Quinones; Rifabutin; Staurosporine; Sunitinib

2005
Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors.
    Clinical colorectal cancer, 2006, Volume: 6 Suppl 1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Everolimus; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunosuppressive Agents; Indoles; Niacinamide; Oligonucleotides; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sirolimus; Staurosporine; Sunitinib; Thiazoles

2006
[Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
    Bulletin du cancer, 2008, Volume: 95, Issue:1

    Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Proteins; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib; Staurosporine; Sunitinib; Thiazoles

2008
FLT3 kinase inhibitors in the management of acute myeloid leukemia.
    Clinical lymphoma & myeloma, 2007, Volume: 8 Suppl 1

    Topics: Benzenesulfonates; Carbazoles; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib

2007
Clinical experience with antiangiogenic therapy in leukemia.
    Current cancer drug targets, 2011, Volume: 11, Issue:9

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Humans; Indoles; Lenalidomide; Leukemia; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib; Thalidomide; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A

2011

Other Studies

23 other study(ies) available for staurosporine and su 11248

ArticleYear
A small molecule-kinase interaction map for clinical kinase inhibitors.
    Nature biotechnology, 2005, Volume: 23, Issue:3

    Topics: Benzamides; Drug Design; Escherichia coli; Escherichia coli Proteins; Imatinib Mesylate; Microchemistry; Pharmaceutical Preparations; Piperazines; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Pyrimidines

2005
Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity.
    Biochemistry, 2007, Aug-21, Volume: 46, Issue:33

    Topics: Adenosine Triphosphate; Amino Acid Sequence; Androstadienes; Binding Sites; Cell Cycle Proteins; Humans; Models, Molecular; Molecular Sequence Data; Peptide Library; Polo-Like Kinase 1; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Substrate Specificity; Wortmannin

2007
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
    Proceedings of the National Academy of Sciences of the United States of America, 2007, Dec-18, Volume: 104, Issue:51

    Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases

2007
A quantitative analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2008, Volume: 26, Issue:1

    Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship

2008
Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
    Journal of medicinal chemistry, 2009, May-28, Volume: 52, Issue:10

    Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Death; Cytotoxins; Drug Resistance, Multiple; Enzyme Inhibitors; HeLa Cells; Humans; Hydrophobic and Hydrophilic Interactions; Indoles; Isatin; Quantitative Structure-Activity Relationship; Substrate Specificity

2009
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:6

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship

2011
Imidazo[2,1-b]thiazole guanylhydrazones as RSK2 inhibitors.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:9

    Topics: Cell Line, Tumor; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Glycogen Synthase Kinase 3; Humans; Hydrazones; Magnetic Resonance Spectroscopy; Ribosomal Protein S6 Kinases; Spectrophotometry, Infrared

2011
Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2.
    Bioorganic & medicinal chemistry, 2011, Sep-15, Volume: 19, Issue:18

    Topics: Binding Sites; Cells, Cultured; Humans; Phosphorylation; Protein Kinase Inhibitors; Structure-Activity Relationship; Time Factors; Vascular Endothelial Growth Factor Receptor-2

2011
Comprehensive analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11

    Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity

2011
Evaluation of potential Myt1 kinase inhibitors by TR-FRET based binding assay.
    European journal of medicinal chemistry, 2013, Volume: 61

    Topics: Dose-Response Relationship, Drug; Fluorescence Resonance Energy Transfer; Glycolipids; Humans; Membrane Proteins; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Structure-Activity Relationship

2013
Modification of a promiscuous inhibitor shifts the inhibition from γ-secretase to FLT-3.
    Bioorganic & medicinal chemistry letters, 2012, Dec-15, Volume: 22, Issue:24

    Topics: Amyloid Precursor Protein Secretases; Animals; Dose-Response Relationship, Drug; Embryo, Nonmammalian; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Humans; Molecular Structure; Phenotype; Recombinant Proteins; Structure-Activity Relationship; Substrate Specificity; Zebrafish

2012
The development of CNS-active LRRK2 inhibitors using property-directed optimisation.
    Bioorganic & medicinal chemistry letters, 2013, Jul-01, Volume: 23, Issue:13

    Topics: Central Nervous System; Central Nervous System Agents; Dose-Response Relationship, Drug; Drug Discovery; High-Throughput Screening Assays; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Molecular Structure; Morpholines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrimidines; Structure-Activity Relationship

2013
Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia.
    European journal of medicinal chemistry, 2014, Oct-06, Volume: 85

    Topics: Animals; Antineoplastic Agents; Aurora Kinase B; Cell Line, Tumor; Chlorocebus aethiops; Drug Design; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia, Myeloid, Acute; Male; Mice; Protein Kinase Inhibitors; Vero Cells; Xenograft Model Antitumor Assays

2014
Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines.
    Journal of medicinal chemistry, 2018, 01-11, Volume: 61, Issue:1

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Molecular Docking Simulation; Protein Conformation; Protein Kinase Inhibitors; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2

2018
Pyrazolo[4,3-b]pyrimido[4,5-e][1,4]diazepine derivatives as new multi-targeted inhibitors of Aurora A/B and KDR.
    European journal of medicinal chemistry, 2018, Oct-05, Volume: 158

    Topics: Animals; Antineoplastic Agents; Aurora Kinase A; Aurora Kinase B; Azepines; Cell Line, Tumor; Humans; Mice; Mice, Nude; Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Vascular Endothelial Growth Factor Receptor-2

2018
Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia.
    Bioorganic & medicinal chemistry, 2022, 02-15, Volume: 56

    Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Cell Line; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Humans; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Receptor, trkA; Structure-Activity Relationship

2022
Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
    Experimental hematology, 2007, Volume: 35, Issue:10

    Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Staurosporine; Sunitinib

2007
FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.
    Blood, 2010, Feb-18, Volume: 115, Issue:7

    Topics: Alleles; Antineoplastic Agents; Benzenesulfonates; Benzothiazoles; Carbazoles; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Furans; Humans; Indazoles; Indoles; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Pyridines; Pyrroles; Sorafenib; Staurosporine; Sunitinib

2010
Colony stimulating factor-1 receptor as a target for small molecule inhibitors.
    Bioorganic & medicinal chemistry, 2010, Mar-01, Volume: 18, Issue:5

    Topics: Benzamides; Binding Sites; Carbazoles; Computer Simulation; Dasatinib; Drug Design; Furans; Humans; Hydrogen Bonding; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor; Staurosporine; Sunitinib; Thiazoles

2010
FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations.
    The oncologist, 2011, Volume: 16, Issue:8

    Topics: Antineoplastic Agents; Benzothiazoles; Carbazoles; Clinical Trials as Topic; Cytokines; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Phenylurea Compounds; Pyrroles; Staurosporine; Sunitinib; Tandem Repeat Sequences

2011
Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase.
    Journal of biochemistry, 2012, Volume: 151, Issue:1

    Topics: Animals; Benzamides; Benzenesulfonates; Binding, Competitive; Cell Line; Dasatinib; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Indazoles; Indoles; Kinetics; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor; Sorafenib; Spodoptera; Staurosporine; Sulfonamides; Sunitinib; Surface Plasmon Resonance; Thiazoles; Transfection

2012
The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.
    Leukemia, 2013, Volume: 27, Issue:6

    Topics: Antineoplastic Agents; Benzothiazoles; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Phenylurea Compounds; Pyrroles; Staurosporine; Sunitinib

2013
A chemical biology approach identifies AMPK as a modulator of melanoma oncogene MITF.
    Oncogene, 2014, May-08, Volume: 33, Issue:19

    Topics: AMP-Activated Protein Kinases; Blotting, Western; Cell Line; Cell Survival; Chromatography, Liquid; Enzyme Inhibitors; Fluorescent Antibody Technique; Humans; Indoles; Mass Spectrometry; Melanocytes; Melanoma; Microphthalmia-Associated Transcription Factor; Oncogenes; Pyrroles; RNA Interference; RNA, Small Interfering; Staurosporine; Sunitinib; Transfection

2014